Enbrel
Court sides with Amgen in Sandoz’ challenge over patent on Enbrel
August 12, 2019Sales and Marketing Enbrel, IP, Novartis Amgen, court, patent, pharma
A US court has sided with Amgen in a legal battle over the patent on blockbuster rheumatoid arthritis drug Enbrel. …
FDA approves first therapy for paediatric psoriasis treatment
November 7, 2016Sales and Marketing Amgen, Enbrel, paediatric, psoriasis
Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. …
FDA approves Novartis Enbrel biosimilar
August 31, 2016Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar, erzeli
Novartis, through its Sandoz division, has announced that the FDA has approved Erelzi (etanercept-szzs), a biosimilar of Amgen’s blockbuster drug …
FDA recommends Novartis’s biosimilar for Enbrel in unanimous vote
July 14, 2016Research and Development, Sales and Marketing Enbrel, FDA, Novartis, Sandoz, biosimilar
Sandoz, a division of Novartis, has announced that a US Food and Drug Administration (FDA) advisory committee has recommended their …
New data shows Sandoz’s Enbrel biosimilar has equivalent efficacy profile
July 7, 2016Research and Development, Sales and Marketing Amgen, EMA, Enbrel, FDA, Novartis, Sandoz, biosimilars
Sandoz has announced new data confirming the equivalent safety and efficacy profile of their biosimilar version of Enbrel (etanercept) in …
Sandoz biosimilars as safe and efficacious as originators, says early trials data
June 9, 2016Research and Development Enbrel, MabThera, Novartis, Sandoz, biosimilars, etanercept, rituximab
Sandoz, a division of Novartis, has presented data at the Annual European Congress of Rheumatology (EULAR 2016) demonstrating the safety …
New data on biosimilars of the big three anti-TNF drugs presented at EULAR 2016
June 8, 2016Research and Development, Sales and Marketing Benepali, Biogen, Enbrel, Flixabi, Humira, Remicade, Samsung Bioepis, biosimilars, eular 2016, sb5
Samsung Bioepis has presented data at EULAR 2016 on three biosimilars of the highly selling anti-TNF drugs Remicade (infliximab), Enbrel …
Amgen raises 2016 outlook after Q1 earnings boost
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Enbrel, etanercept, financial results, financials, sales rise
Amgen (NASDAQ: AMGN) has upgraded their 2016 outlook after posting an increase of 10% in revenues for the first quarter …
FDA approves Lilly’s plaque psoriasis drug Taltz
March 23, 2016Research and Development, Sales and Marketing Eli Lilly, Enbrel, Taltz, plaque psoriasis
The US Food and Drug Administration (FDA) has approved Eli Lilly’s Taltz (ixekizumab) for the treatment of moderate-to-severe plaque psoriasis in …
Eli Lilly’s plaque psoriasis treatment impresses in Phase III trials
March 7, 2016Research and Development, Sales and Marketing Eli Lilly, Enbrel, ixekizumab, psoriasis
Eli Lilly has announced late-stage trial data showing ixekuzimab treatment resulted in clinically meaningful improvements in as early as one …
First Enbrel biosimilar launches in UK
February 16, 2016Manufacturing and Production, Research and Development Enbrel, Samsung Bioepis, eternacept, rheumatoid arthritis
Following its approval by the European Commission in January, Benepali has become the first biosimilar of Pfizer/Amgen’s Enbrel (etanercept) to …
Biosimilars: Can the US catch up in 2016?
February 12, 2016Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars
What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …
Samsung beats pharma to develop first EU-approved Enbrel biosimilar
January 18, 2016Manufacturing and Production Benepali, CHMP, EMA, Enbrel, Samsung, Samsung Bioepis, etanercept, positive opinion
Samsung Bioepis – the collaboration between Samsung Biologics and Biogen Idec, has become the first company to have a biosimilar …
Baxalta’s Enbrel biosimilar measures up in late-stage study
January 13, 2016Research and Development Amgen, Baxalta, Enbrel, Pfizer, biosimilar, etanercept, rheumatoid arthritis
Having emerged from its mega-merger deal with Shire, Baxalta is back on its drug development day job – and has …
New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs
December 16, 2015Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin
NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …
